Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002315430 | SCV000849305 | uncertain significance | Inborn genetic diseases | 2021-11-30 | criteria provided, single submitter | clinical testing | The c.8323A>G (p.I2775V) alteration is located in exon 45 (coding exon 44) of the VPS13B gene. This alteration results from a A to G substitution at nucleotide position 8323, causing the isoleucine (I) at amino acid position 2775 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001830592 | SCV002082674 | uncertain significance | Cohen syndrome | 2020-09-21 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004742592 | SCV005364658 | uncertain significance | VPS13B-related disorder | 2024-07-26 | no assertion criteria provided | clinical testing | The VPS13B c.8248A>G variant is predicted to result in the amino acid substitution p.Ile2750Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |